Efficacy and Safety of the Probiotic Saccharomyces Boulardii for the Prevention and Therapy of Gastrointestinal Disorders

Overview

Journal Therap Adv Gastroenterol

Publisher Sage Publications

Specialty Gastroenterology

Date 2012 Mar 17

PMID 22423260

Citations 122

Authors

Theodoros Kelesidis

Charalabos Pothoulakis

Affiliations

Soon will be listed here.

Abstract

Several clinical trials and experimental studies strongly suggest a place for Saccharomyces boulardii as a biotherapeutic agent for the prevention and treatment of several gastrointestinal diseases. S. boulardii mediates responses resembling the protective effects of the normal healthy gut flora. The multiple mechanisms of action of S. boulardii and its properties may explain its efficacy and beneficial effects in acute and chronic gastrointestinal diseases that have been confirmed by clinical trials. Caution should be taken in patients with risk factors for adverse events. This review discusses the evidence for efficacy and safety of S. boulardii as a probiotic for the prevention and therapy of gastrointestinal disorders in humans.

Citing Articles

as a single trigger of food protein-induced enterocolitis syndrome: Seven case reports.

Hwang J, Jang H World J Clin Cases. 2025; 13(6):98111.

PMID: 40012823 PMC: 11612675. DOI: 10.12998/wjcc.v13.i6.98111.

Effect of Isolation Ruminal Yeast from Ruminants on In Vitro Ruminal Fermentation.

Wilachai K, Paengkoum P, Taethaisong N, Thitisak P, Poonsuk K, Loor J Vet Sci. 2025; 12(2).

PMID: 40005915 PMC: 11861707. DOI: 10.3390/vetsci12020155.

Atopic Dermatitis and Atopic Keratoconjunctivitis: New Insights in the Analyses of Microbiota and Probiotic Effect.

Petrillo F, Buonanno A, Fedi L, Galdiero M, Reibaldi M, Tamburini B Int J Mol Sci. 2025; 26(4).

PMID: 40003928 PMC: 11855157. DOI: 10.3390/ijms26041463.

Fungi in the Gut Microbiota: Interactions, Homeostasis, and Host Physiology.

Liu H, Li S, Ogamune K, Ahmed A, Kim I, Zhang Y Microorganisms. 2025; 13(1).

PMID: 39858841 PMC: 11767893. DOI: 10.3390/microorganisms13010070.

How Does DSM 34246 (Canobios-BL) Supplementation Impact the Fecal Parameters of Healthy Adult Dogs?.

Lonigro N, Perondi F, Bruni N, Bigliati M, Costale A, Pagani E Vet Sci. 2025; 12(1).

PMID: 39852920 PMC: 11769235. DOI: 10.3390/vetsci12010045.

References

Mumy K, Chen X, Kelly C, McCormick B . Saccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling events. Am J Physiol Gastrointest Liver Physiol. 2007; 294(3):G599-609. PMC: 3212754. DOI: 10.1152/ajpgi.00391.2007. View

Dinleyici E, Eren M, Yargic Z, Dogan N, Vandenplas Y . Clinical efficacy of Saccharomyces boulardii and metronidazole compared to metronidazole alone in children with acute bloody diarrhea caused by amebiasis: a prospective, randomized, open label study. Am J Trop Med Hyg. 2009; 80(6):953-5. View

Guslandi M . Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis. J Clin Gastroenterol. 2010; 44(5):385. DOI: 10.1097/MCG.0b013e3181cb4233. View

Pant N, Marcotte H, Brussow H, Svensson L, Hammarstrom L . Effective prophylaxis against rotavirus diarrhea using a combination of Lactobacillus rhamnosus GG and antibodies. BMC Microbiol. 2007; 7:86. PMC: 2194776. DOI: 10.1186/1471-2180-7-86. View

Bartlett J . Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002; 346(5):334-9. DOI: 10.1056/NEJMcp011603. View

Htwe K, Yee K, Tin M, Vandenplas Y . Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in Myanmar children: a randomized controlled study. Am J Trop Med Hyg. 2008; 78(2):214-6. View

Buts J, Bernasconi P, Vaerman J, Dive C . Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci. 1990; 35(2):251-6. DOI: 10.1007/BF01536771. View

Gaon D, Garcia H, Winter L, Rodriguez N, Quintas R, Gonzalez S . Effect of Lactobacillus strains and Saccharomyces boulardii on persistent diarrhea in children. Medicina (B Aires). 2003; 63(4):293-8. View

Buts J, de Keyser N, De Raedemaeker L . Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines. Pediatr Res. 1994; 36(4):522-7. DOI: 10.1203/00006450-199410000-00019. View

10.

Weese J . Evaluation of deficiencies in labeling of commercial probiotics. Can Vet J. 2004; 44(12):982-3. PMC: 340366. View

11.

McFarland L . Unraveling the causes of negative studies: a case of S boulardii for the prevention of antibiotic-associated diarrhea. Rev Med Chil. 2009; 137(5):719-20. DOI: /S0034-98872009000500021. View

12.

Hwang J, Kang K, Kang Y, Kim A . Probiotic gastrointestinal allergic reaction caused by Saccharomyces boulardii. Ann Allergy Asthma Immunol. 2009; 103(1):87-8. DOI: 10.1016/S1081-1206(10)60154-8. View

13.

Canil C, Rosenshine I, Ruschkowski S, Donnenberg M, Kaper J, Finlay B . Enteropathogenic Escherichia coli decreases the transepithelial electrical resistance of polarized epithelial monolayers. Infect Immun. 1993; 61(7):2755-62. PMC: 280918. DOI: 10.1128/iai.61.7.2755-2762.1993. View

14.

Im E, Pothoulakis C . [Recent advances in Saccharomyces boulardii research]. Gastroenterol Clin Biol. 2010; 34 Suppl 1:S62-70. DOI: 10.1016/S0399-8320(10)70023-3. View

15.

McFarland L . Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis. 2007; 5(2):97-105. DOI: 10.1016/j.tmaid.2005.10.003. View

16.

Gorbach S . Probiotics and gastrointestinal health. Am J Gastroenterol. 2000; 95(1 Suppl):S2-4. DOI: 10.1016/s0002-9270(99)00806-0. View

17.

Elmer G, McFarland L, Surawicz C, Danko L, Greenberg R . Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther. 1999; 13(12):1663-8. DOI: 10.1046/j.1365-2036.1999.00666.x. View

18.

Duman D, Bor S, Ozutemiz O, Sahin T, Oguz D, Istan F . Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacterpylori eradication. Eur J Gastroenterol Hepatol. 2005; 17(12):1357-61. DOI: 10.1097/00042737-200512000-00015. View

19.

Guslandi M . Treatment of irritable bowel syndrome with Saccharomyces boulardii. J Clin Gastroenterol. 2011; 45(8):740-1. DOI: 10.1097/MCG.0b013e3182166c76. View

20.

Buts J, De Keyser N, Stilmant C, Sokal E, Marandi S . Saccharomyces boulardii enhances N-terminal peptide hydrolysis in suckling rat small intestine by endoluminal release of a zinc-binding metalloprotease. Pediatr Res. 2002; 51(4):528-34. DOI: 10.1203/00006450-200204000-00021. View